Arvinas, Inc. (ARVN)

NASDAQ: ARVN · IEX Real-Time Price · USD
68.51
1.43 (2.13%)
Jan 26, 2022 4:00 PM EST - Market closed

Company Description

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

Arvinas, Inc.
Arvinas Logo
CountryUnited States
Founded2015
IPO DateSep 27, 2018
IndustryPharmaceuticals
SectorHealth Care
Employees179

Contact Details

Address:
5 Science Park
New Haven, CT 06511
United States
Phone203 535 1456
Websitearvinas.com

Stock Details

Ticker SymbolARVN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001655759

Key Executives

NamePosition
Dr. John G. Houston Ph.D.Chief Executive Officer, President and Director
Sean A. Cassidy CPA, M.B.A., CPAChief Financial Officer and Treasurer
Dr. Ian Taylor Ph.D.Chief Scientific Officer
Dr. Ronald A. PeckChief Medical Officer
Dr. Craig M. CrewsFounder, Chief Scientific Advisor and Member of Scientific Advisory Board
Jeff BoyleVice President of Investor Relations
Matthew Batters J.D.General Counsel
Dr. Robert KleinfieldChief Development Officer
Dr. Randy Teel Ph.D.Senior Vice President of Corporate and Business Development
Steve WeissVice President of Human Resources

Latest SEC Filings

DateTypeTitle
Jan 4, 20224Statement of changes in beneficial ownership of securities
Dec 21, 20214Statement of changes in beneficial ownership of securities
Dec 16, 20214Statement of changes in beneficial ownership of securities
Dec 10, 20218-KCurrent report
Nov 17, 20214Statement of changes in beneficial ownership of securities
Nov 15, 20214Statement of changes in beneficial ownership of securities
Nov 9, 20214Statement of changes in beneficial ownership of securities
Nov 3, 20214Statement of changes in beneficial ownership of securities
Nov 3, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 3, 20218-KCurrent report
View All SEC Filings